Ionis Pharmaceuticals (IONS) FCF Margin (2009 - 2026)

Ionis Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 331.01% for Q1 2026.

• On a quarterly basis, FCF Margin fell 20689.0% year-over-year to 331.01% in Q1 2026; TTM through Mar 2026 was 151.33%, a 7393.0% decrease from a year earlier, with the FY2025 full-year figure at 28.51%, up 4895.0% from the prior year.
• FCF Margin declined to 331.01% in Q1 2026 per IONS's latest filing, from 53.13% in the prior quarter.
• Across five years, FCF Margin topped out at 6951.65% in Q2 2025 and bottomed at 331.01% in Q1 2026.
• The 5-year median for FCF Margin is 62.51% (2024), against an average of 328.63%.
• Across the five-year window, FCF Margin surged 700764 bps in 2025 and plunged 20689 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 134.53% in 2022, then jumped by 108 bps to 10.38% in 2023, then tumbled by 702 bps to 62.51% in 2024, then grew by 15 bps to 53.13% in 2025, then tumbled by 523 bps to 331.01% in 2026.
• Per Business Quant, the three latest IONS FCF Margin figures stand at 331.01% (Q1 2026), 53.13% (Q4 2025), and 87.23% (Q3 2025).